Eplerenone-mediated aldosterone blockade prevents renal fibrosis by reducing renal inflammation, interstitial cell proliferation and oxidative stress

Kidney and Blood Pressure Research

Volumn 37, Issue 6, 2013, Pages 557-566

  Chen, Hui ^a   Sun, Feng ^b   Zhong, Xiaoshi ^a   Shao, Yuebin ^a   Yoshimura, Ashio ^c   Liu, Yan ^a  

^a GUANGZHOU RED CROSS HOSPITAL   (China)

^b GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

^c SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

Author keywords

SMA; 8 OHdG; Acrolein; ED 1; Eplerenone; Fibrosis; Inflammation; MCP 1; PCNA; Unilateral ureteral obstruction

Indexed keywords

ALDOSTERONE; ALPHA SMOOTH MUSCLE ACTIN; CREATININE; CYCLINE; EPLERENONE; MONOCYTE CHEMOTACTIC PROTEIN 1; POTASSIUM;

ALDOSTERONE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BODY WEIGHT; CELL ACTIVATION; CELL INFILTRATION; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; KIDNEY FIBROSIS; KIDNEY INJURY; LEYDIG CELL; MACROPHAGE; MALE; MEAN ARTERIAL PRESSURE; MONOCYTE; MORPHOLOGICAL TRAIT; NEPHRITIS; NONHUMAN; OXIDATIVE STRESS; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RAT; RENAL PROTECTION; SYSTOLIC BLOOD PRESSURE; UREA NITROGEN BLOOD LEVEL; URETER OBSTRUCTION; IMMUNOHISTOCHEMISTRY; MORPHOMETRICS; UNILATERAL URETERAL OBSTRUCTION;

ANIMALS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FIBROSIS; INFLAMMATION; MALE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; NEPHRITIS, INTERSTITIAL; OXIDATIVE STRESS; RANDOM ALLOCATION; RATS; RATS, WISTAR; SPIRONOLACTONE;

EID: 84891130376     PISSN: 14204096     EISSN: 14230143     Source Type: Journal    
DOI: 10.1159/000355736     Document Type: Article

References (35)

1. Delyani JA: Mineralocorticoid receptor antagonists: The evolution of utility and pharmacology. Kidney Int 2000;57:1408-1411.
2. Wimett L, Laustsen G: Inspra improves survival for chf patients. Nurse Pract 2004;29:56-59.
3. Weinberger MH, Roniker B, Krause SL, Weiss RJ: Eplerenone, a selective aldosterone blocker, in mild-tomoderate hypertension. Am J Hypertens 2002;15:709-716.
4. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-1321.
5. Krum H, Nolly H, Workman D, He W, Roniker B, Krause S, Fakouhi K: Efficacy of eplerenone added to reninangiotensin blockade in hypertensive patients. Hypertension 2002;40:117-123.
6. Epstein M, Alexander JC, Roniker B: Efficacy and safety of eplerenone, a novel and selective aldosterone receptor antagonist (SARA), in patients with mild to moderate hypertension [Abstract]. Hypertension 1999;33:1075.
7. Cattran DC, Greenwood C, Ritchie S: Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin a nephropathy: A comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy. Am J Kidney Dis 1994;23:247-254.
8. Ishidoya S, Morrissey J, McCracken R, Reyes A, Klahr S: Angiotensin ii receptor antagonist ameliorates renal tubulointerstitial fibrosis caused by unilateral ureteral obstruction. Kidney Int 1995;47:1285-1294.
9. Rosenberg ME, Smith LJ, Correa-Rotter R, Hostetter TH: The paradox of the renin-angiotensin system in chronic renal disease. Kidney Int 1994;45:403-410.
10. Epstein M: Aldosterone and the hypertensive kidney: Its emerging role as a mediator of progressive renal dysfunction: A paradigm shift. J Hypertens 2001;19:829-842.
11. Epstein M, Williams GH, Weinberger M, Lewin A, Krause S, Mukherjee R, Patni R, Beckerman B: Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006;1:940-951.
12. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT, Jr.: Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998;31:451-458.
13. Eddy AA: Interstitial macrophages as mediators of renal fibrosis. Exp Nephrol 1995;3:76-79.
14. Klahr S, Morrissey J: Obstructive nephropathy and renal fibrosis. Am J Physiol Renal Physiol 2002;283:F861-875.
15. Nishida M, Okumura Y, Fujimoto S, Shiraishi I, Itoi T, Hamaoka K: Adoptive transfer of macrophages ameliorates renal fibrosis in mice. Biochem Biophys Res Commun 2005;332:11-16.
16. Rocha R, Funder JW: The pathophysiology of aldosterone in the cardiovascular system. Ann N Y Acad Sci 2002;970:89-100.
17. Stier C Jr., Zuckerman A, Harashima H, Chander P: Antioxidants reduce aldosterone-induced renal vascular injury in stroke-prone spontaneously hypertensive rats [Abstract]. Proc Int Soc Hypertens 2000; P4.03.
18. Fujihara CK, Malheiros DM, Zatz R, Noronha IL: Mycophenolate mofetil attenuates renal injury in the rat remnant kidney. Kidney Int 1998;54:1510-1519.
19. Jepsen FL, Mortensen PB: Interstitial fibrosis of the renal cortex in minimal change lesion and its correlation with renal function. A quantitative study. Virchows Arch A Pathol Anat Histol 1979;383:265-270.
20. Vieira JM, Jr., Mantovani E, Rodrigues LT, Delle H, Noronha IL, Fujihara CK, Zatz R: Simvastatin attenuates renal inflammation, tubular transdifferentiation and interstitial fibrosis in rats with unilateral ureteral obstruction. Nephrol Dial Transplant 2005;20:1582-1591.
21. Trachtman H, Weiser AC, Valderrama E, Morgado M, Palmer LS: Prevention of renal fibrosis by spironolactone in mice with complete unilateral ureteral obstruction. J Urology 2004;172:1590-1594.
22. Rocha R, Chander PN, Zuckerman A, Stier CT, Jr.: Role of aldosterone in renal vascular injury in strokeprone hypertensive rats. Hypertension 1999;33:232-237.
23. Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon EG: Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 2003;63:1791-1800.
24. Zhou X, Ono H, Ono Y, Frohlich ED: Aldosterone antagonism ameliorates proteinuria and nephrosclerosis independent of glomerular dynamics in l-name/shr model. Am J Nephrol 2004;24:242-249.
25. Nielsen FT, Jensen BL, Hansen PB, Marcussen N, Bie P: The mineralocorticoid receptor antagonist eplerenone reduces renal interstitial fibrosis after long-term cyclosporine treatment in rat: Antagonizing cyclosporine nephrotoxicity. BMC Nephrol 2013;14:42.
26. Feng M, Whitesall S, Zhang Y, Beibel M, D'Alecy L, DiPetrillo K: Validation of volume-pressure recording tailcuff blood pressure measurements. Am J Nephrol 2008;21:1288-1291.
27. Ibrahim J, Berk BC, Hughes AD: Comparison of simultaneous measurements of blood pressure by tail-cuff and carotid arterial methods in conscious spontaneously hypertensive and wistar-kyoto rats. Clin Exp Hypertens 2006;28:57-72.
28. Kelman Z: Pcna: Structure, functions and interactions. Oncogene 1997;14:629-640.
29. Kitada K, Nakano D, Liu Y, Fujisawa Y, Hitomi H, Shibayama Y, Shibata H, Nagai Y, Mori H, Masaki T, Kobori H, Nishiyama A: Oxidative stress-induced glomerular mineralocorticoid receptor activation limits the benefit of salt reduction in Dahl salt-sensitive rats. PLoS One 2012;7:e41896.
30. Tokuyama H, Wakino S, Hara Y, Washida N, Fujimura K, Hosoya K, Yoshioka K, Hasegawa K, Minakuchi H, Homma K, Hayashi K, Itoh H: Role of mineralocorticoid receptor/Rho/Rho-kinase pathway in obesityrelated renal injury. Int J Obes (Lond) 2012;36:1062-1071.
31. Nagase M, Fujita T: Role of Rac1-mineralocorticoid-receptor signalling in renal and cardiac disease. Nat Rev Nephrol 2013;9:86-98.
32. Alpers CE, Hudkins KL, Floege J, Johnson RJ: Human renal cortical interstitial cells with some features of smooth muscle cells participate in tubulointerstitial and crescentic glomerular injury. Clin J Am Soc Nephrol 1994;5:201-209.
33. Zeisberg M, Kalluri R: The role of epithelial-to-mesenchymal transition in renal fibrosis. Int J Mol Med 2004;82:175-181.
34. Guo G, Morrissey J, McCracken R, Tolley T, Liapis H, Klahr S: Contributions of angiotensin ii and tumor necrosis factor-alpha to the development of renal fibrosis. Am J Physiol Renal Physiol 2001;280:F777-F785.
35. Sies H: Oxidative stress: Oxidants and antioxidants. Exp Physiol 1997;82:291-295.